期刊文献+

洛匹那韦逆转LLC/cMOAT细胞多药耐药的作用 被引量:1

Reversal effects of lopinavir on multidrug resistant LLC/cMOAT cells
下载PDF
导出
摘要 目的研究洛匹那韦对LLC/cMOAT细胞株多药耐药的逆转作用及其可能机制。方法采用四甲基偶氮唑盐方法(MTT)检测洛匹那韦对细胞株LLC/CMV和LLC/cMOAT细胞生存的影响,并检测阿霉素(ADM)、长春新碱(VCR)、环磷酰胺(CTX)、顺铂(DDP)对上述细胞株的半数抑制浓度(IC50)。应用流式细胞术检测洛匹那韦处理后细胞内化疗药物阿霉素相关的荧光强度变化。结果 LLC/cMOAT细胞对ADM、VCR、DDP有不同程度的耐药,对CTX未产生耐药;洛匹那韦在浓度小于10.0μmol.L-1时,对LLC/cMOAT细胞无明显细胞毒性作用;用2.5μmol.L-1洛匹那韦处理后,LLC/cMOAT细胞对VCR和DDP的敏感性增高,浓度提高至5.0μmol.L-1时,敏感性明显提高;用洛匹那韦处理后LLC/cMOAT细胞内ADM的蓄积增加,并表现为浓度依赖;细胞周期检测分析显示,使用洛匹那韦处理0、4、8、16 h后,G1期细胞百分比由(42.65±3.75)%分别增至(56.77±2.37)%、(68.13±4.30)%、(70.25±5.12)%,与0 h G1期细胞数比较差异显著(P<0.05);使用洛匹那韦处理细胞48 h后,凋亡率增高且呈时间和浓度依赖性。结论洛匹那韦可以部分逆转LLC-cMOAT的多药耐药,这种逆转可能与增加细胞内化疗药物蓄积,诱导细胞G1期阻滞,增强细胞凋亡有关。 Aim To study the reversal effects of lopinavir on the multidrug resistance of LLC/cMOAT cells.Methods The sensitivity of LLC/CMV and LLC/cMOAT cells to several chemotherapeutics,the cytoactivity of LLC/CMV and LLC/cMOAT cells treated with different concentrations of lopinavir and the inhibition rate of ADM,VCR,CTX and DDP treated with different concentration of lopinavir to LLC/CMV and LLC/cMOAT cells were evaluated with MTT assay.The IC50 of different agents was counted.Intracellular concentration of ADM and cellular cycle analysis were detected by flow cytometer(FCM).Results LLC/cMOAT cells were resistant to ADM,VCR and DDP but not to CTX.When the concentration less than 10 μmol·L^-1,lopinavir was not significantly cytotoxic to LLC/CMV and LLC/cMOAT cells.After treatment with 2.5 μmol·L^-1 lopinavir,the chemo-sensitivity of LLC/cMOAT cells to VCR and DDP was enhanced and much higher when treated with 5.0 μmol·L^-1of lopinavir.When treated with 2.5 and 5.0 μmol·L^-1 lopinavir,ADM accumulation in LLC/cMOAT cells were enhanced significantly in a concentration-dependent manner.Cellular cycle analysis demonstrated that 0,4,8,16 hours after co-cultured with lopinavir the amount of cells at G0/G1 phase increased from(42.65±3.75)% at 0 h to(70.25±5.12)% at 16 h(P〈0.05).The cell apoptosis rate was increased in a time-and concentration-dependent manner.Conclusion Lopinavir could perform reverse effects on the multidrug resistance of LLC/ cMOAT cells and the reversal effects correlate to lopinavir concentration.The underlying mechanism might involve the growth arrest at G1,the increasing of intracellular drug concentration and promoting apoptosis.
出处 《安徽医药》 CAS 2010年第11期1263-1265,共3页 Anhui Medical and Pharmaceutical Journal
关键词 洛匹那韦 LLC/cMOAT 多药耐药 逆转 lopinavir LLC/cMOAT multidrug resistance reversal
  • 相关文献

参考文献10

  • 1Ford JM,Hait WN.Pharmacologic circumvention of multidrug resistance[J].Cytotechnology,1993,12:171-212.
  • 2Ramalingam S,Belani CP.Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer[J].Semin Thorac Cardiovasc Surg,2003,15(4):437-8.
  • 3Katragadda S,Budda B,Anand BS,et al.Role of efflux pumps and metabolizing enzymes in drug delivery[J].Expert Opin Drug Deliv,2005,2(4):683-705.
  • 4车国卫,周清华.肺癌的筛查和早期诊断[J].中国肺癌杂志,2003,6(6):412-417. 被引量:31
  • 5El-Sheikh AA,Heuvel JJ,Koenderink JB,et al.Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP)2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport[J].Pharmacol Exp Ther,2007,320(1):229-35.
  • 6Okumura H,Chen ZS,Sakou M,et al.Reversal of P-Glycoprotein and Multidrug-Resistance Protein-Mediated Drug Resistance in KB Cells by 5-O-benzoylated taxinine K[J].Mol Pharmacol,2000,58:1563-9.
  • 7Eilers M,Roy U,Mondal D.MRP (ABCC) transporters-mediated efflux of anti-HIV drugs,saquinavir and zidovudine,from human endothelial cells[J].Exp Biol Med(Maywood),2008,233(9):1149-60.
  • 8Janneh O,Jones E,Chandler B,et al.Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes[J].Antimicrob Chemother,2007,60:987-93.
  • 9Pal D,Mitra AK.MDR-and CYP3A4-mediated drug-herbal interactions[J].Life Sci,2006,78(18):2131-45.
  • 10Mor G,Montagna MK,Alvero AB.Modulation of apoptosis to reverse chemoresistance[J].Methods Mol Biol,2007,414(2):1-12.

二级参考文献29

  • 1[1]James R. Screening and early dectection of lung cancer. Lung Cancer,2003,41(Suppl 3)∶S52.
  • 2[3]Edward F, Patz EF Jr. Screening for lung cancer. Lung Cancer,2003,41(Suppl 2)∶S73-S74.
  • 3[4]Flehinger BJ, Melamed MR. Current status of screening for lung cancer. Chest Surg Clin N Am,1994,4(1)∶1-15.
  • 4[5]Henschke CI. Early lung cancer action project: overall design and findings from baseline screening. Cancer,2000,89(11 Suppl)∶2474-2482.
  • 5[6]Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT vs radiography. Radiology,1996,201(3)∶798-802.
  • 6[7]Sone S, Li F, Yang ZG, et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer,2001,84(1)∶25-32.
  • 7[8]David E, Stephen J, James R, et al. Evaluation of nodules detected by screening for lung cancer with low dose spiral computed tomography. Lung Cancer,2003,41(Suppl 2)∶S40.
  • 8[9]Kaneko M, Toshiaki K, Noriyuki M, et al.Screening for lung cancer with low dose spiral CT and sputum cytology: Results of Anti-Lung Cancer Association Project. Lung Cancer,2003,41(Suppl 2)∶S40.
  • 9[10]Melvyn S, Todd H, Lynn C, et al. Lung cancer screening with helical CT: Evidence for a stage shift? Lung Cancer,2003,41(Suppl 2)∶ S40-S41.
  • 10[11]Rob J, Harry J, Willem PTM, et al. Trial design and first screening results from the NEderLands-leuvens longkanker screening ONderzoek, a prospective randomized clinical trial on lung cancer screening by spiral CT. Lung Cancer,2003,41(Suppl 2)∶S158.

共引文献30

同被引文献10

  • 1Hasson H,Galli L,Gallotta G. HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment:a randomised pilot study(KaMon)[J].{H}New Microbiologica,2012,(04):469-474.
  • 2Cooper C,la-Porte C,Tossonian H. A pilot,prospective,open-label simplification study to evaluate the safety,efficacy,and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients:the MONOCO study[J].{H}HIV CLINICAL TRIALS,2012,(04):179-188.
  • 3Lambert-Niclot S,Masquelier B,Cohen Codar I. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice[J].{H}Journal of Antimicrobial Chemotherapy,2012,(10):2487-2493.
  • 4Josephson F,Andersson MC,Flamholc L. The relation between treatment outcome and efavirenz,atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naive HIV-1 infected patients[J].{H}EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY,2010,(04):349-357.
  • 5何勇;陈仕云;余三喜.利托那韦异构体杂质的合成研究及控制方法[P]中国:102786494,2012.
  • 6姚亚敏,孙建军,陈军,刘晓茜,卢洪洲,张丽军.LC-MS/MS法同时测定洛匹那韦和利托那韦的血浆浓度[J].药学学报,2010,45(2):279-282. 被引量:12
  • 7李家明,何勇,周鹏,徐云根,彭家志,盛日正.阿魏酰胍丁胺类似物的设计、合成及Na^+/H^+交换器-1抑制活性[J].药学学报,2011,46(8):936-941. 被引量:4
  • 8邬皓,李家明,盛日正,周鹏,钟国琛,蒋丽娜.川芎嗪芳酸醚甘氨酸衍生物合成及抗血小板聚集活性[J].安徽医药,2011,15(8):937-940. 被引量:3
  • 9何勇,陈仕云,吴宗好.瑞格列奈的合成[J].中国医药工业杂志,2012,43(2):84-86. 被引量:5
  • 10姚亚敏,沐俊,孙骥,马芳,卢洪洲,张丽军.洛匹那韦药代动力学的研究进展[J].药学实践杂志,2012,30(5):336-339. 被引量:11

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部